drugset / Trial / NCT04402151
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
Phase 2
Recruiting
50 enrolled
Weill Medical College of Cornell University
National Cancer Institute (NCI) · collabTelix Pharmaceuticals (Innovations) Pty Limited · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.
Timeline
- Start
- 2020-06-30
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Gallium-68 labeled PSMA-HBED-CC | Diagnostic / imaging agent | — | Intravenous |